Credit Suisse’s Moleculin Biotech MBRX Stock Holding History

Credit Suisse’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5	Closed	-$29K	–	4119
2017 Q3	$29K	Buy	+5	New	+$26.4K	﹤0.01%	4153

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LNWWM

Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Credit Suisse's MBRX Position: Q4 2017 in Review

Credit Suisse sold out of Moleculin Biotech (MBRX) in Q4 2017, closing a stake of 5 shares — an estimated $29K sold.

Credit Suisse first reported a position in MBRX in Q3 2017 and held it in 1 quarter. The position peaked at $29K in Q3 2017. 14 funds tracked by Wall St. Rank hold MBRX as of Q4 2017.

Credit Suisse reported no remaining Moleculin Biotech position as of Q4 2017 after selling out during the quarter.
Credit Suisse sold 5 Moleculin Biotech shares in Q4 2017, an estimated $29K.
Credit Suisse first reported a position in Moleculin Biotech in Q3 2017 and held it in 1 quarter.
Credit Suisse's Moleculin Biotech position peaked at $29K in Q3 2017.
14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2017.

Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.